Test Price
2,800 AED✅ Home Collection Available
UBE3A Gene Angelman Syndrome Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
This comprehensive genetic test utilises Next-Generation Sequencing (NGS) to analyse the UBE3A gene for pathogenic variants causing Angelman syndrome, achieving 99.9% diagnostic sensitivity. The service includes ISO-certified cold-chain home collection via VIP mobile phlebotomy (daily 8 AM – 11 PM), post-test clinical counselling by a DHA-licensed Consultant Medical Genetics specialist, and full compliance with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The UBE3A NGS test detects single-nucleotide variants, small insertions/deletions, and copy-number changes across the entire UBE3A gene, providing a definitive molecular diagnosis of Angelman syndrome (ICD-10-CM: Q93.5). Results guide neurological management, genetic counselling, and recurrence risk assessment for families.
| Feature | Our Test (Precision NGS) | Closest Alternative (Standard Panel) |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) with Sanger confirmation | Targeted mutation analysis / MLPA only |
| Variant Detection | SNVs, indels, exon-level CNVs, UPD | Limited to known deletions/duplications |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| LOINC Code | 82907-1 (UBE3A gene mutation analysis) | Multiple or unassigned |
Physician Insight & Safety Protocols
“A positive UBE3A variant result provides powerful molecular confirmation of Angelman syndrome, yet it must always be correlated with the full clinical picture including developmental history, EEG abnormalities, and behavioural phenotype. I strongly advise against making therapeutic decisions based solely on this genetic report. A multidisciplinary team evaluation — involving neurology, clinical genetics, and developmental paediatrics — is essential for optimal long-term management.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Important Advisory & Safety Notices
⚠️ Medication Continuity Advisory
Do not alter or stop any prescribed anti-epileptic, behavioural, or supportive therapy without direct consultation with your treating physician. Sudden discontinuation may trigger seizures, withdrawal symptoms, or clinical deterioration.
Exclusion Criteria & Emergency Red Flags
- Exclusion: This test is not indicated for asymptomatic individuals without clinical suspicion or family history of Angelman syndrome; it does not replace a comprehensive neurological work-up.
- Exclusion: Patients with active bleeding disorders or inability to provide a blood/DNA sample should consult the laboratory prior to collection.
- 🚨 Emergency Red Flag: If your child exhibits new-onset seizures, acute loss of developmental skills, or severe behavioural outbursts, seek immediate emergency medical attention.
Patient FAQ & Clinical Guidance
1. What exactly does the UBE3A gene test for Angelman syndrome detect?
This advanced NGS test analyses the UBE3A gene to identify pathogenic variants responsible for Angelman syndrome. It detects single-nucleotide changes, small insertions/deletions, and copy-number variations, including those arising from uniparental disomy. The result confirms the molecular subtype, which directly informs prognosis and recurrence risk counselling.
2. What sample types are accepted, and how long do results take?
We accept whole blood (EDTA), extracted DNA, or dried blood spot on an FTA card. The standard turnaround time is 3 to 4 weeks. Home collection is available daily from 8 AM to 11 PM, with cold-chain transport to our ISO-certified laboratory.
3. Do I need a referral, and can I use insurance?
A requisition from a neurologist, clinical geneticist, or developmental paediatrician is recommended for pre-authorisation. Our team verifies insurance coverage directly via WhatsApp (+971 54 548 8731) before sample collection, and we work with major UAE insurers. Self-pay options are also available.
4. Will I receive genetic counselling after the result?
Yes, a post-test tele-consultation with a DHA-licensed Consultant Medical Genetics specialist is included in the service. The session covers result interpretation, recurrence risk, and family screening recommendations where appropriate.
UAE Regulatory & Data Privacy Adherence
🏛️ Regulatory Compliance Framework
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – Full data sovereignty and patient privacy
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – Secure health data handling
- Federal Decree-Law No. 4 of 2016 on Medical Liability – Clinical safety and informed consent
- ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139)
- DHA Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
🩺 Hospital-grade home collection & tele-guidance by DHA-licensed medical professionals.
Clinical & Logistical Metadata
| Test Name | UBE3A Gene Angelman Syndrome Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | Q93.5 |
| LOINC Code | 82907-1 (Verify LOINC) |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians